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NOVELTY STATEMENT 
x We explored the potential of ȕ-agonist salbutamol inhalation as a screening test to 
identify those at risk of abnormal cardiac repolarisation during hypoglycaemia. We 
provide a detailed description of electrophysiological effects of a single-dose 
administration of nebulised salbutamol and of hyperinsulinaemic-hypoglycaemic 
clamp in young people with type 1 diabetes. 
x We confirm that both stimuli ± salbutamol and hyperinsulinaemic-hypoglycaemic 
clamp have pro-arrhythmogenic electrophysiological effects causing prolongation of 
QTc and TpTend interval duration, decrease in T-wave amplitude (Tamp) and T-wave area 
symmetry (Tsym). 
x The magnitude of electrophysiological changes induced by these two stimuli did not 
show any relationship as measured by a statistically significant correlation in any of the 
examined variables. 
x An individual`s electrophysiological response to inhaled salbutamol does not appear to 
be useful in predicting an individual`s electrophysiological response to hypoglycaemia. 
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ABSTRACT 
Aims 
Hypoglycaemia causes QT-interval prolongation and should be considered as pro-
arrhythmogenic. Salbutamol, a ȕ-adrenoreceptor agonist also causes QT-interval 
prolongation. We hypothesised that the magnitude of electrophysiological changes induced by 
salbutamol and hypoglycaemia might relate to each other and that salbutamol could be used as 
a non-invasive screening tool for predicting an individual`s electrophysiological response to 
hypoglycaemia. 
Methods 
18 individuals with type 1 diabetes were administered 2.5mg of nebulised salbutamol. 
Participants then underwent a hyperinsulinaemic-hypoglycaemic clamp (2.5mmol/l for 1 
hour). During both experiments heart rate, serum potassium (and catecholamines during the 
clamp) were measured and a high-resolution ECG was recorded at pre-set timepoints. Cardiac 
repolarisation was measured by QT-interval duration adjusted for heart rate (QTc), T-wave 
amplitude (Tamp), T-peak to T-end interval duration (TpTend) and T-wave area symmetry (Tsym). 
The maximum changes versus baseline in both experiments were assessed for their linear 
dependence. 
Results  
Salbutamol administration caused QTc and TpTend prolongation and a decrease in Tamp and Tsym. 
Hyperinsulinaemic-hypoglycaemic clamp caused increased plasma catecholamines, 
hypokalaemia, QTc and TpTend prolongation and a decrease in Tamp and Tsym. No significant 
correlations were found between maximum changes in QTc (r=0.15, 95% CI [-0.341 ± 0.576], 
p=0.553), TpTend (r=0.075, 95% CI [-0.406 ± 0.524], p=0.767), Tsym (r=0.355, 95% CI [-0.132 
± 0.706], p=0.149) or Tamp (r=0.148, 95% CI [-0.347 ± 0.572], p=0.558) in both experiments. 
Conclusions 
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Salbutamol and hyperinsulinaemic-hypoglycaemic clamp both caused pro-arrhythmogenic 
electrophysiological changes in people with type 1 diabetes but the magnitude of these changes 
were not related in a given individual. Salbutamol cannot be used to assess an individual`s 
electrophysiological response to hypoglycaemia. 
 
KEYWORDS 
Hypoglycaemia, QT-interval, salbutamol, electrophysiological changes, hypoglycaemic 
clamp, type 1 diabetes, young people. 
 
INTRODUCTION 
Considerable evidence indicates that hypoglycaemia is a pro-arrhythmogenic event during both 
experimental [1, 2] and clinical conditions [3, 4]. Hypoglycaemia causes QTc prolongation 
together with pro-arrhythmogenic changes in rate-independent T-wave characteristics (TpTend, 
Tsym) via catecholamine release, hypokalaemia and inhibition of rapid delayed rectifier 
potassium channels (IKr) [5]. Cases of bradycardia, atrial fibrillation, atrial flutter or ventricular 
ectopic beats linked with hypoglycaemia have been previously reported [3, 4, 6, 7]. Although 
hypoglycaemia continues to be very common in people with type 1 diabetes [8], sudden 
QRFWXUQDO GHDWKV µGHDG-in-EHG¶ V\QGURPH [9], in which hypoglycaemia-induced malignant 
arrhythmias have been implicated, are fortunately very rare [10].  This indicates that the risk 
of arrhythmias is confined to only a few individuals although whether increased susceptibility 
is related to genetic factors, autonomic dysfunction other unrecognised influences remains 
unclear. This discrepancy offered us an opportunity to identify those at greatest risk of QTc 
lengthening and potentially hypoglycaemia-induced arrhythmias, particularly since therapeutic 
or technological interventions might prevent the development of malignant cardiac 
arrhythmias.  
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6DOEXWDPRO LV D ȕ-DGUHQRUHFHSWRU DJRQLVW ZLWK SUHGRPLQDQW ȕ-activity commonly used for 
treatment of asthma and chronic obstructive pulmonary disease (COPD) [11]. Salbutamol`s 
SRVLWLYHFKURQRWURSLFHIIHFWKDVEHHQFODVVLFDOO\OLQNHGZLWKȕ- adrenoreceptor stimulation, 
while QTc-prolonging and hypokalaemic effects are mediated by ȕ-adrenoreceptor activity 
[12]. We have previously shown that elevated catecholamine levels are the predominant cause 
of QTc prolongation during hypoglycaemia [13]. Furthermore, pre-treatment with a selective 
ȕ-adrenoreceptor blocker atenolol [11] resulted in significant blunting of the QTc prolongation 
during experimental hypoglycaemia in people with type 1 diabetes [14]. We therefore 
hypothesised that establishing electrophysiological changes induced by salbutamol inhalation 
might offer a practical, non-invasive approach to predicting an individual`s 
electrophysiological responses induced by hypoglycaemia. This raised the possibility of 
identifying high-risk candidates who might be suitable for potential prophylactic treatment 
ZLWKȕ-adrenoreceptor blockers or implantable cardioverter defibrillator.  Thus the aim of this 
study was to examine the potential of inhaled salbutamol as a screening test for those at greatest 
risk of abnormal cardiac repolarization during hypoglycaemia. 
 
PARTICIPANTS AND METHODS 
Eighteen adults with type 1 diabetes mellitus DJH 50) were recruited from local diabetes 
outpatient clinics. Exclusion criteria were presence of ischaemic heart disease, cerebrovascular 
or peripheral vascular disease, asthma or COPD, presence of severe microvascular diabetic 
complications (diabetic maculopathy with severe visual impairment or estimated glomerular 
filtration rate (eGFR CKD-EPI) <30ml-1 min-1 1.73m-2 and medication with ȕ-blocking or QT-
interval prolonging agents. Written informed consent was obtained from all participants and 
the study received local ethics approval. 
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Baseline assessment and salbutamol challenge 
Each potential participant had a 12-lead ECG performed and individuals with branch block or 
atrial fibrillation were excluded. Arterial blood pressure, body mass index (BMI), haemoglobin 
A1c (HbA1c), urea and electrolytes, total cholesterol and triglyceride levels were obtained during 
the initial study visit. Cardiovascular autonomic tests were performed [15, 16] to establish 
cardiovascular autonomic neuropathy status [17]. Participants were instructed to avoid 
vigorous exercise, caffeine and smoking 24 hours prior to morning testing. Capillary blood 
glucose (BG) was measured immediately prior to administration of salbutamol to ensure 
participants were not hypoglycaemic (BG 3.5mmol/l). Subsequently, 2.5mg salbutamol was 
administered via a face mask. Blood pressure, heart rate, serum potassium and 5 minute (min) 
high-resolution 3-lead ECG were measured at baseline and 10, 20, 40 and 60min after 
salbutamol administration. 
Hyperinsulinaemic-hypoglycaemic clamp 
Following the salbutamol challenge, participants underwent a hyperinsulinaemic-
hypoglycaemic clamp. Both study visits took place at least 4 weeks apart. Participants were 
instructed to measure BG before meals, on going to bed, at 03:00 and on waking on the day of 
the clamp to ensure no hypoglycaemia (BG 3.5mmol/l) occurred 24 hours prior to the clamp. 
Upon arrival at 08:30, an intravenous cannula was inserted into the antecubital fossa of the 
dominant arm for initially insulin and sodium chloride (NaCl) and later for insulin and dextrose 
infusions. An infusion of 0.9% NaCl with potassium chloride (KCl) (20mmol KCl for each 
500ml of 0.9% NaCl) was initiated at a rate of 125ml/hr. For the following 4 hours BG was 
stabilised in euglycaemic range (5-10mmol/l) using a variable intravenous insulin infusion 
(Actrapid, Novo Nordisk Ltd, Crawley, UK) adjusted based on BG readings every 30min. At 
12:00 a retrograde cannula was inserted in the non-dominant hand in a warming chamber at 
55oC for arterialised BG, potassium and catecholamine sampling. A hypoglycaemic clamp 
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procedure began at 13:00. A primed continuous intravenous insulin infusion was administered 
at 60mU m-2 min-1 along with 20% dextrose commenced 4min later at a variable rate, adjusted 
according to arterialised BG concentrations measured every 5min (Analox GM9D Glucose 
Direct Analyser, Analox Instruments Ltd., Stourbridge, UK) for the whole duration of the 
clamp. Participants were blinded to BG values. From the start of the clamp, BG was maintained 
at 5mmol/l for 60min (timepoints 30 EU1 ± 60 EU2), then was lowered to 2.5mmol/l over the 
following 30min (until the 90 EU/HYPO timepoint) and was maintained at 2.5mmol/l for 
60min (timepoints 90 EU/HYPO, 120 HYPO1 and 150 HYPO2). Blood pressure, heart rate 
and high-resolution 3-lead ECG were recorded and blood samples for potassium and 
catecholamine levels were taken at baseline, 30 EU1, 60 EU2, 90 EU/HYPO, 120 HYPO1 and 
150 HYPO2 timepoints as well as 30min after the end of the procedure (180 Recov. timepoint). 
To measure catecholamines, 6ml of whole blood was collected into chilled lithium heparin 
tubes containing 50µL of EGTA/glutathione preservative and centrifuged at 4oC, 3000rpm for 
10min. The resulting supernatant was stored at -80oC until assayed by high-performance liquid 
chromatography. 
ECG and cardiac repolarisation 
Three orthogonal ECG leads (X, Y and Z) were low-pass filtered (40Hz) and the isoelectric 
line was subtracted. For each lead, an average beat was calculated from a 5min recording. A 
composite wave was then calculated from averaged beats as the square root of X2+Y2+Z2 and 
was used for further analysis of cardiac repolarisation. Semi-automatic custom-built software 
was used to detect the fiducial points and to calculate the parameters of T-wave morphology. 
Measurement of the QT-interval was based on the tangent method and Bazett correction for 
heart rate was applied (QTc). T-wave morphology was characterized by the T-wave amplitude 
(Tamp), normalised to the baseline [18], the T-peak to T-end interval duration (TpTend), TpTend 
corrected for heart rate (TpTend) and T-wave area symmetry ratio (Tsym), which was defined as 
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the area under the T-wave from T-wave onset to T-peak divided by the area under the T wave 
between T-peak to T-end  [19]. The onset and offset of the T-wave were characterised by 
tangents at the ascending and descending sections of the T-wave. 
Statistical analysis 
Statistical analysis was performed with SPSS (version 23; IBM, Chicago, USA). Graphing was 
completed using GraphPad Prism (version 7.03, GraphPad Software, Inc., San Diego, USA). 
Repeated measures analysis of variance (ANOVA) was applied to both salbutamol and clamp 
studies. The Greenhouse-Geisser correction was used to test the effect of time where the 
sphericity condition was violated according to 0DXFKO\¶VWHVW. Where a significant effect of 
time was identified, contrasts to baseline were used to compare means of variables at multiple 
timepoints during salbutamol challenge (T10, T20, T40 and T60) and euglycaemic timepoint 
(60 EU1) and hypoglycaemic timepoint (150 HYPO2) of hypoglycaeamic clamp procedure 
versus their corresponding baseline.  For all parameters, normality of residuals was confirmed 
by revision of QQ plots. Linear dependence between variables was examined using Pearson 
correlation coefficient (r). P<0.05 was deemed statistically significant and correlations of >0.6 
were considered clinically relevant. 
 
RESULTS 
Baseline characteristics and salbutamol challenge 
Baseline participant characteristics are shown in Table 1. Following administration of 2.5mg 
nebulised salbutamol, systolic and diastolic blood pressure readings did not change 
significantly (Table 2). Serum potassium concentrations showed a non-significant trend 
towards lower values, but remained within the normal range (Fig. 1a). A trend towards higher 
heart rates compared to baseline was observed from T20 onwards although did not increase 
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significantly (p=0.170 for the group) (Fig. 1b). Both QTc interval and TpTend significantly 
prolonged following salbutamol inhalation (p<0.001 for the group). QTc interval was 
significantly prolonged at all timepoints vs. baseline with a maximum mean difference 18.0ms 
at T20 (95% CI: 12.5 ± 23.4) (Fig. 1c). Similarly, TpTend interval duration was significantly 
prolonged at all timepoints vs. baseline with a maximum mean difference 7.4ms at T20 (95% 
CI: 4.5 ± 10.3) (Fig. 1d). T-wave area symmetry (Tsym) decreased (p=0.010 for the group) after 
salbutamol administration. This difference was statistically significant at all timepoints with a 
maximum mean difference vs. baseline -0.082 at T20 (95% CI: -0.127 ± -0.038) (Fig. 1e). The 
normalised T-wave amplitude (Tamp) dropped during the salbutamol challenge (p<0.001 for the 
group). The difference was statistically significant at all timepoints with a maximum mean 
difference vs. baseline -0.127 at T40 (95% CI: -0.177 ± -0.078) (Fig. 1f). Numerical values for 
all observed variables during salbutamol challenge are listed in Table 2. 
Hyperinsulinaemic-hypoglycaemic clamp  
Systolic and diastolic blood pressure readings did not differ significantly between baseline, 
euglycaemia and hypoglycaemia (Table 2). Blood glucose levels during the clamp are shown 
in Fig. 2a. Adrenaline levels significantly increased during the hypoglycaemic part of the clamp 
(ǻ vs. baseline 2.67mmol/l, 95% CI: 1.89 ± 3.45, p<0.001), but did not differ between baseline 
and euglycaemia (Fig. 2b). Serum potassium levels dropped significantly during the 
euglycaemic part of the clamp (ǻ-0.43mmol/l, 95% CI: -0.50 ± -0.37, p<0.001) and decreased 
further at hypoglycaemia150 HYPO2 ǻ-0.81mmol/l, 95% CI: -1.02 ± -0.59, p<0.001) (Fig. 
2c). Heart rate increased gradually during the clamp but the difference was not significant for 
the group (p=0.069) (Fig. 2d). QTc interval was significantly prolonged at euglycaemia 
ǻ19.1ms, 95% CI: 13.8 ± 24.4, p<0.001) and further prolonged at hypoglycaemia ǻ56.9ms, 
95% CI: 43.2±70.5, p<0.001) (Fig. 2e). Similarly, TpTend interval was prolonged at 
euglycaemia ǻms, 95% CI: 8.4 ± 17.0, p<0.001) and further prolonged at hypoglycaemia 
10 
 
ǻms, 95% CI: 24.8 ±4 9.5, p<0.001) (Fig. 2f). T-wave amplitude dropped to 75% of the 
baseline value at euglycaemia ǻ-0.243, 95% CI: -0.282 ± -0.204, p<0.001) and dropped further 
to 57% at hypoglycaemia ǻ-0.433, 95% CI: -0.492 ± -0.373, p<0.001) (Fig. 2g). T-wave area 
symmetry decreased progressively and was significantly lower vs. baseline at both 
euglycaemia (ǻ-0.167, 95% CI: -0.240 ± -0.095, p=0.001) and hypoglycaemia (ǻ-0.390, 95% 
CI: -0.534 ± -0.246, p<0.001). The T-waves became symmetric (Tsym~1) at hypoglycaemia 
(Fig. 2h). Numerical values for all observed variables during hyperinsulinaemic 
hypopglycaemic clamp are listed in Table 2. 
Correlations between responses to salbutamol inhalation and to hyperinsulinaemic-
hypoglycaemic clamp 
We examined whether the magnitude of salbutamol-induced changes in cardiac repolarisation 
correlated with changes induced during the hyperinsulinaemic-hypoglycaemic clamp. For this 
purpose, the maximum change in each parameter vs. baseline was calculated for the salbutamol 
challenge and for the hypoglycaemic part of the clamp. The maximum differences in both 
challenges were then assessed for their linear dependence. There was no statistically significant 
correlation between the magnitude of the QTc interval change during salbutamol challenge and 
during hyperinsulinaemic-hypoglycaemic clamp (r=0.15, 95% CI [-0.341 ± 0.576], p=0.553). 
Additionally, no statistically significant correlations were detected between the changes in 
TpTend (r=0.075, 95% CI [-0.406 ± 0.524], p=0.767), Tsym (r=0.355, 95% CI [-0.132 ± 0.706], 
p=0.149) or Tamp (r=0.148, 95% CI [-0.347 ± 0.572], p=0.558) during salbutamol challenge and 
hyperinsulinaemic-hypoglycaemic clamp.   
 
DISCUSSION  
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In the present VWXG\ ZH VRXJKW WR GHWHUPLQH ZKHWKHU QHEXOLVHG ȕ-adrenoreceptor agonist 
salbutamol induces electrophysiological changes that were related in their character and 
magnitude, to hypoglycaemia-induced electrophysiological changes in young people with type 
1 diabetes.  
We showed that administration of 2.5mg nebulised salbutamol led to significant prolongation 
of QTc interval duration with concomitant TpTend interval prolongation, flattening of the T-
wave and a change towards more symmetric T-wave. These findings are largely in keeping 
with previously published data indicating that salbutamol causes QTc interval prolongation, T-
wave flattening and in some participants, ST-segment depression and emergence of U-waves 
[20]. To our knowledge, we are the first to report that salbutamol inhalation results in 
significant TpTend interval prolongation and a change in T-wave area symmetry. TpTend and 
Tsym are measures of dispersion of cardiac repolarisation, an important factor in initiation of 
ventricular arrhythmias [19, 21] and TpTend prolongation has been shown to be associated with 
increased risk of sudden cardiac death [22]. In our study we observed non-significant trends 
towards increased heart rate and decreased serum potassium levels. Given the previously 
reported significant changes in these characteristics in similar settings [23], this probably 
reflects the relatively small number of participants. 6LQFHWKHLQWURGXFWLRQRIȕ-adrenoreceptor 
agonists in the treatment of obstructive airway disease in the 1960s, concerns have been raised 
regarding their short-term and long-term cardiovascular safety profile and this issue has 
remained controversial. Case reports suggesting increased risk of cardiac arrhythmias linked 
with the use of salbutamol have been published [24], however the data from larger studies and 
meta-analyses have been conflicting. Some studies, have reported a significantly increased risk 
for adverse cardiovascular events [25], whereas others did not [26]. Careful use of ȕ-
adrenoreceptor agonists, especially in specific patient populations such as in those with 
underlying cardiac conditions, is therefore warranted.  
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During the hyperinsulinaemic euglycaemic part of the clamp we observed a decrease in plasma 
potassium levels with concomitant QTc and TpTend interval prolongation and decreased T-wave 
amplitude (Tamp) and more symmetric T-waves (decreased T-wave area symmetry ratio Tsym). 
Significant increases in plasma catecholamine levels were detected during the subsequent 
hyperinsulinaemic-hypoglycaemic part of the clamp, which resulted in an additional decrease 
of plasma potassium levels, QTc and TpTend prolongation and decreased Tamp and Tsym. These 
biochemical and electrophysiological findings confirm our previous studies indicating that 
hypoglycaemia causes an acquired long-QT syndrome with pro-arrhythmogenic changes in T-
wave morphology and that these changes are mainly caused by a combination of insulin-
induced hypokalaemia and hypoglycaemia-stimulated catecholamine release [1, 13]. 
Importantly, similar electrophysiological changes are present during both experimental [1] and 
clinical hypoglycaemia in various groups of individuals ± in children and adolescents [27], in 
young and otherwise healthy people with type 1 diabetes [4] or in middle-aged people with 
type 2 diabetes and present cardiovascular risk factors [3]. We also detected a non-significant 
trend towards increased heart rate during the hypoglycaemic part of the clamp in keeping with 
changes observed in our previously published studies [13, 14]. 
Lastly, we examined whether the character and magnitude of salbutamol-induced changes in 
cardiac repolarisation correlated with changes induced by a hyperinsulinaemic-hypoglycaemic 
clamp. We did not find any significant correlation in any of the examined electrophysiological 
variables, which, at first sight and given the current knowledge about the mechanisms causing 
hypoglycaemia and salbutamol-induced QTc interval prolongation, appears surprising.  
Clearly, one possible explanation is that with this number of participants our study lacked 
sufficient statistical power to demonstrate a statistically significant association. Eighteen 
participants is a relatively large number for studies inducing experimental hypoglycaemia using 
a hyperinsulinaemic clamp and this number provided sufficient 80% power to identify a 
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statistically significant r value of 0.6. We reasoned that it would be necessary to identify this 
strength of association if we were to justify inhaled salbutamol as a screening test. The upper 
limits of the 95% CI of correlations for QTc, TpTend and Tamp in our study do not include values 
of >0.6 suggesting these results are neither statistically significant nor clinically relevant. The 
rather wide 95% CI for Tsym includes the clinically relevant correlation however, which 
suggests that this result is not statistically significant but might be potentially clinically relevant 
and further studies on larger number of participants will be required. 
Our hypothesis was based on our previous work which showed that QTc interval prolongation 
induced by hyperinsulinaemic-hypoglycaemic clamp in healthy individuals was completely 
abolished by atenolol [13]. In the same individuals, keeping the serum potassium levels within 
the normal range (3.5 ± 4.5mmol/l) during a hyperinsulinaemic-hypoglycaemic clamp on a 
different occasion only partially diminished the magnitude of QTc prolongation [13]. Atenolol 
was subsequently shown to significantly reduce QTc prolongation during hyperinsulinaemic-
hypoglycaemic clamp in individuals with type 1 diabetes [14]. These data therefore implicated 
sympathoadrenal activation as a major driver of hypoglycaemia-induced QTc prolongation. 
Both sympathoadrenal response, independently of its trigger, and hypoglycaemia cause 
hypokalaemia. Catecholamines and salbutamol FDXVH K\SRNDODHPLD YLD ELQGLQJ WR ȕ-
adrenoreceptors with resulting formation of cyclic adenosine monophosphate (cAMP) and 
subsequent stimulation of membrane-bound sodium potassium adenosine triphosphatase 
(Na+/K+-ATPase) [12]. This ion channel causes a shift of potassium from the extracellular to 
the intracellular compartment with resulting hypokalaemia. Hypoglycaemia causes 
hypokalaemia via two mechanisms ± by sympathoadrenal activation and via the effects of 
insulin which stimulates potassium cellular uptake by elevation and increased sensitivity to 
intracellular sodium, translocation and activation of Na+/K+-ATPase and by inhibition of 
potassium cellular efflux [28]. Thus, mechanisms behind ȕ-adrenergic and hypoglycaemia-
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induced hypokalaemia are similar, but not completely identical. Thirdly, hypoglycaemia causes 
QTc prolongation by direct inhibition of IKr channels in the cardiomyocyte membrane [29]. The 
resulting prolongation of action potential duration, together with intracellular calcium loading 
in the cardiomyocyte caused by increaVHGȕ-adrenergic stimulation, represent the two major 
pro-arrhythmic pathomechanisms [5]. The one obvious difference between the salbutamol 
challenge and hyperinsulinaemic-hypoglycaemic clamp in our study was the presence of 
hypokalaemia (K+ <3.5mmol/l) during the clamp. Salbutamol administration, in our hands, did 
not lead to hypokalaemia and potassium levels were relatively constant during the observed 
period of 60min post administration.  It is possible, that the effect of hyperinsulinaemia-induced 
sympathoadrenal activation with hypokalaemia and potential direct effect of hypoglycaemia 
on IKr channels [29] influenced the resulting electrophysiological changes in a given individual. 
Consistent with our previous observations that sympathoadrenal activation appears to be the 
main driver of hypoglycaemia-induced electrophysiological changes, we wonder whether the 
response is also modulated by hypokalaemia and direct inhibitory effect of hypoglycaemia on 
IKr channels.  
There are other limitations to the current study. First, we could not control for the variable 
impairment in hypoglycaemia induced sympathoadrenal responses among individuals with 
type 1 diabetes during a given hypoglycaemic stimulus. This known heterogeneity may be an 
important reason for the limited correlation.   
Second, we examined electrophysiological responses during experimental hypoglycaemia 
rather than during clinical hypoglycaemia. Circulating insulin concentrations during 
experimental hypoglycaemia are greater than those generally observed in clinical 
hypoglycaemia with resulting greater electrophysiological effects due to more pronounced 
hypokalaemia [1, 30].  
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Third, it is unclear to what extent, variable degrees of autonomic dysfunction contributed to 
the lack of a relationship.  Most of participants did not have cardiovascular autonomic 
neuropathy (15/18), 3 had some degree of autonomic dysfunction as measured by 
cardiovascular autonomic function tests but none had definite cardiovascular autonomic 
neuropathy.  
In summary, we have described electrophysiological changes following a single dose of 
nebulised salbutamol and subsequently during a hyperinsulinaemic-hypoglycaemic clamp in 
18 young people with type 1 diabetes. Both stimuli caused prolongation of QTc and TpTend 
intervals and decreased T-wave amplitude (Tamp) and T-wave area symmetry (Tsym). The 
magnitude of electrophysiological changes induced by these two stimuli does not correlate in 
a given individual, however. Salbutamol therefore does not appear to be a useful screening tool 
to assess an individual`s electrophysiological response to hyperinsulinaemic hypoglycaemia. 
Further search for ways of identifying those with diabetes at greatest risk of QTc lengthening 
and potentially hypoglycaemia-induced arrhythmias is warranted. The current emergence of 
continuous glucose monitoring (CGM) into clinical practice and the increasing sophistication 
of ambulatory Holter ECG monitoring may offer a more promising approach particularly as it 
involves direct measurement of arrhythmias.  Screening for those exhibiting arrhythmias rather 
than identifying a surrogate measure of abnormal cardiac repolarization such as QT interval 
may be a better approach in management of this rare but devastating syndrome. 
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Table 1. Baseline participant characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are displayed as mean ± SD. Abbreviations: CAN ± cardiovascular autonomic 
neuropathy. 
 
 
 
 
 
 
 
 
Number of participants, n  18 
Age (years)  35 ± 7 
Male, n (%)  12 (66.7%) 
Duration of diabetes (years) 18.2 ± 7.5 
BMI (kg/m2) 26.1 ± 4.3 
HbA1C  
  % 8.4 ± 0.8 
  mmol/mol  68 ± 9  
Systolic BP (mmHg) 123 ± 12 
Diastolic BP (mmHg) 74 ± 7 
Heart rate (bpm) 69 ± 11 
Baseline QTc (ms) 390 ± 26 
Sodium (mmol/l) 137 ± 2.4 
Potassium (mmol/l) 4.11  ± 0.23 
Creatinine (umol/l) 71 ± 14.0 
Urea (mmol/l) 4.5 ± 1.6 
Total cholesterol (mmol/l) 4.7 ± 0.6 
Triglycerides (mmol/l) 1.2 ± 0.6 
CAN status  
  no CAN, n (%) 15/18 (83.3%) 
  possible CAN, n (%) 3/18 (16.7%) 
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Table 2. Numerical values for examined variables during salbutamol challenge and during 
hyperinsulinaemic-hypoglycaemic clamp 
 
n=18 SALBUTAMOL CHALLENGE HYPERINSULINAEMIC-HYPOGLYCAEMIC CLAMP 
Timepoints Baseline T10 T20 T40 T60 Baseline EU  HYPO 
SBP (mmHg) 122 ±  12 121 ± 10 122 ± 10 121 ± 9 122 ± 10 117 ± 15 116 ± 14 118 ± 17 
DBP (mmHg) 74 ± 7 72 ± 9 72 ± 6 72 ± 6 73 ± 7 72 ± 10 74 ± 10 67 ± 11 
Heart rate (bpm) 69 ± 11 70 ± 8 71 ± 12 71 ± 12 71 ± 12 67 ± 12 71 ± 12 73 ±  10 
Potassium 
(mmol/l) (n = 13)a 4.04 ± 0.21 4.03 ± 0.32 4.01 ± 0.32 4.02 ± 0.28 4.02 ± 0.29 3.85 ± 0.24 
3.42 ± 0.15 
*** 
3.01 ± 0.23 
*** 
QTc (ms) 390 ± 26 405 ± 33 
** 
408 ± 28 
*** 
405 ± 27 
*** 
405 ± 29 
*** 
403 ± 25 422 ± 27 
*** 
459 ± 34 
*** 
TpTend (ms) 67.3 ± 9.6 74.7 ± 14.3 
*** 
74.3 ± 13.5 
*** 
73.3 ± 12.3 
*** 
72.4 ± 10.5 
*** 
71.5 ± 8.1 84.4 ± 12.6 
*** 
108.6 ± 25.8 
*** 
TpTendc (ms) 71.6 ± 10.8 80.3 ± 16.4 
*** 
80.5 ± 14.4 
*** 
79.2 ± 13.1 
*** 
78.3 ± 11.7 
*** 
75.1 ± 7.1 91.1 ± 14.7 
*** 
119.9 ± 31.4 
*** 
Tamp 1.0 
0.88 ± 0.09 
*** 
0.88 ± 0.10 
*** 
0.89 ± 0.10 
*** 
0.88 ± 0.09 
*** 
1.0 0.75 ± 0.08 
*** 
0.57 ± 0.11 
*** 
Tsym 1.46 ± 0.23 
1.39 ± 0.24 
* 
1.38 ± 0.26 
** 
1.38 ± 0.24 
** 
1.40 ± 0.23 
** 
1.35 ± 0.16 1.19 ± 0.15 
** 
0.96 ± 0.19 
*** 
Adrenaline 
(nmol/l) - - - - - 0.37 ± 0.20 0.38 ± 0.18 
3.04 ± 1.59 
*** 
Noradrenaline 
(nmol/l) - - - - - 1.16 ± 0.29 1.20 ± 0.32 
1.85 ± 0.65 
*** 
 
 
Data are displayed as mean ± SD. aPlasma potassium was measured in 13 participants only. 
Repeated measures ANOVA was used in both experiments, followed by contrasts vs the 
corresponding baseline. Greenhouse-Geisser correction was used in case of violated 
assumption of sphericity. Abbreviations: EU ± euglycaemia, 60min after the start of the 
protocol (60 EU1 timepoint), HYPO ± hypoglycaemia, 150min after the start of the protocol 
(150 HYPO2 timepoint), SBP - systolic blood pressure, DBP ± diastolic blood pressure. 
Asterisks (*) denote statistically significant changes vs corresponding baseline. *p<0.05, 
**p<0.01, ***p<0.001.  
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Figure 1. Biochemical and electrophysiological variables during salbutamol challenge. 1a. 
Serum potassium. 1b. Heart rate. 1c. QTc interval duration. 1d. TpTend interval duration. 1e. T-
wave area symmetry (Tsym). 1f. Normalised T-wave amplitude (Tamp). Repeated measures 
ANOVA with contrasts vs. baseline. Greenhouse-Geisser correction was used where sphericity 
was violated. Data are displayed as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2. Biochemical and electrophysiological variables during hyperinsulinaemic-
hypoglycaemic clamp. 2a. Serum arterialised blood glucose. 2b. Serum adrenaline. 2c. Serum 
potassium. 2d. Heart rate. 2e. QTc interval duration. 2f. TpTend interval duration. 2g. Normalised 
T-wave amplitude (Tamp) 2h. T-wave area symmetry (Tsym). Abbreviations: 30 EU1 and 60 
EU2 ± euglycaemic timepoints 30 and 60min after the start of the protocol, 90 EU/HYPO ±
transition from euglycaemia to hypoglycaemia, 120 HYPO1 and 150 HYPO2 ± hypoglycaemic 
timepoints 120 and 150min after the start of the protocol, 180 Recov. ± recovery time. For 
further details please see Materials and Methods. Repeated measures ANOVA with contrasts 
vs. baseline. Greenhouse-Geisser correction was used where sphericity was violated. Data are 
displayed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
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